AU2021248867A1 - Antiviral compounds and method for treating RNA viral infection, particularly COVID-19 - Google Patents

Antiviral compounds and method for treating RNA viral infection, particularly COVID-19 Download PDF

Info

Publication number
AU2021248867A1
AU2021248867A1 AU2021248867A AU2021248867A AU2021248867A1 AU 2021248867 A1 AU2021248867 A1 AU 2021248867A1 AU 2021248867 A AU2021248867 A AU 2021248867A AU 2021248867 A AU2021248867 A AU 2021248867A AU 2021248867 A1 AU2021248867 A1 AU 2021248867A1
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
group
ring
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021248867A
Other languages
English (en)
Inventor
Tai-Sen Soong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of AU2021248867A1 publication Critical patent/AU2021248867A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2021248867A 2020-03-30 2021-03-18 Antiviral compounds and method for treating RNA viral infection, particularly COVID-19 Pending AU2021248867A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063001723P 2020-03-30 2020-03-30
US63/001,723 2020-03-30
US202063053908P 2020-07-20 2020-07-20
US63/053,908 2020-07-20
PCT/US2021/022976 WO2021202114A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating rna viral infection, particularly covid-19

Publications (1)

Publication Number Publication Date
AU2021248867A1 true AU2021248867A1 (en) 2022-12-01

Family

ID=77920792

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021248867A Pending AU2021248867A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating RNA viral infection, particularly COVID-19
AU2021249224A Abandoned AU2021249224A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis B and hepatitis D

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021249224A Abandoned AU2021249224A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis B and hepatitis D

Country Status (11)

Country Link
US (2) US20210308137A1 (enExample)
EP (2) EP4126846A1 (enExample)
JP (2) JP2023520882A (enExample)
KR (2) KR20230004549A (enExample)
CN (1) CN116075502B (enExample)
AU (2) AU2021248867A1 (enExample)
BR (2) BR112022019558A2 (enExample)
CA (2) CA3179372A1 (enExample)
IL (2) IL296927B2 (enExample)
TW (2) TW202203915A (enExample)
WO (2) WO2021202115A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102641010B1 (ko) 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956064B2 (en) * 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
CN102036561A (zh) * 2008-02-29 2011-04-27 赛林药物股份有限公司 蛋白激酶调节剂
KR20120044281A (ko) * 2009-04-17 2012-05-07 사일린 파마슈티칼스, 인크 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법
SG179163A1 (en) * 2009-09-16 2012-05-30 Cylene Pharmaceuticals Inc Novel tricyclic protein kinase modulators
WO2011063398A1 (en) * 2009-11-23 2011-05-26 Cylene Pharamaceuticals, Inc. Polymorphs and salts of a kinase inhibitor
RU2607453C2 (ru) * 2009-12-04 2017-01-10 Сенхва Байосайенсиз, Инк. Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы
TWI534148B (zh) * 2014-02-13 2016-05-21 生華生物科技股份有限公司 吡唑並嘧啶前藥及其使用方法
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
AU2021241591A1 (en) * 2020-03-24 2022-10-20 Michael W. BURNET Anti-infective and anti-viral compounds and compositions
WO2021247367A1 (en) * 2020-06-02 2021-12-09 Yale University Compounds and compositions for treating, ameliorating, and/or preventing sars-cov-2 infection and/or complications thereof

Also Published As

Publication number Publication date
IL296927B2 (en) 2025-11-01
CA3179167A1 (en) 2021-10-07
WO2021202114A1 (en) 2021-10-07
US20210308110A1 (en) 2021-10-07
KR20230004549A (ko) 2023-01-06
EP4126846A1 (en) 2023-02-08
CN116075502A (zh) 2023-05-05
BR112022019554A2 (pt) 2022-12-06
KR20230004550A (ko) 2023-01-06
US20210308137A1 (en) 2021-10-07
TW202203915A (zh) 2022-02-01
CA3179372A1 (en) 2021-10-07
CN116075502B (zh) 2024-04-12
WO2021202115A1 (en) 2021-10-07
IL296927B1 (en) 2025-07-01
IL296927A (en) 2022-12-01
JP2023520882A (ja) 2023-05-22
US11696911B2 (en) 2023-07-11
BR112022019558A2 (pt) 2022-12-06
AU2021249224A1 (en) 2022-12-01
IL296924A (en) 2022-12-01
JP2023520883A (ja) 2023-05-22
EP4126845A4 (en) 2024-05-01
EP4126845A1 (en) 2023-02-08
TW202203914A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
US20170226121A1 (en) Modulators of virus assembly as antiviral agents
EP3813834A1 (en) New crbn modulators
CN109251212A (zh) 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
WO2020069117A1 (en) Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
WO2021205290A1 (en) Compounds and method of treating covid-19
US11696911B2 (en) Antiviral compounds and method for treating RNA viral infection, particularly COVID-19
AU2022269564A1 (en) Class iia histone deacetylase (hdac) degrader ligands and methods of use thereof
WO2021207052A1 (en) Arginine methyltransferase 5 (prmt5) degraders and uses thereof
WO2020143798A1 (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
TW202031655A (zh) 對抗b型肝炎病毒(hbv)之新穎6,7-二氫-4h-吡唑并[4,3-c]吡啶脲活性劑
HK40086507A (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
HK40086507B (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
US20230364074A1 (en) Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting
AU2021293907A1 (en) Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an E3-ligase system
JP7495758B2 (ja) マクロライド化合物及びその慢性呼吸器疾患の治療用途
US8815878B1 (en) Spiro hemiaminals for treating viral diseases
RU2407738C1 (ru) Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
CN119874668A (zh) 主蛋白酶调节剂及其应用
CN113861176A (zh) 一种黄病毒抑制剂
WO2020245372A1 (en) Heterocyclic immunomodulators as pdl1 checkpoint inhibitor